Visus CEO updates on lead product candidate, 2021 pipeline

Conferences|AAO

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.


See more AAO coverage here

Related Videos
Related Content

Glaucoma 360: Hypotension and glaucoma progression

February 4th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Glaucoma 360: An update on IOLs - when and how to use them

February 4th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Glaucoma 360: A bird's-eye view of innovation

February 3rd 2023

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Glaucoma 360: Hypotension and glaucoma progression

February 4th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Glaucoma 360: An update on IOLs - when and how to use them

February 4th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Glaucoma 360: A bird's-eye view of innovation

February 3rd 2023

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Glaucoma 360: Hypotension and glaucoma progression

February 4th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Glaucoma 360: An update on IOLs - when and how to use them

February 4th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Glaucoma 360: A bird's-eye view of innovation

February 3rd 2023

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.